Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672858 | 1.00 | PLG (0.46) | PLGPLAUHTR7CYP19A1GLO1 | |
| SCHEMBL3352870 | 0.89 | HTR7 (0.58) | HTR7KMT2AF2RL3 | |
| SCHEMBL31735444 | 0.84 | MEN1 (0.46) | PLGPLAUHTR7KMT2ASLC6A2 | |
| SCHEMBL3355607 | 0.84 | HTR7 (0.49) | PLGPLAUHTR7CYP19A1KMT2A | |
| SCHEMBL7085455 | 0.83 | MTNR1A (0.53) | HTR7KMT2A | |
| SCHEMBL2479169 | 0.82 | HTR7 (0.47) | PLGPLAUHTR7CYP19A1SLC6A2 | |
| SCHEMBL8545929 | 0.82 | KRAS (0.47) | PLGPLAUHTR7KMT2ASLC6A2 | |
| SCHEMBL30785020 | 0.81 | MAPT (0.51) | PLGPLAUHTR7CYP19A1KMT2A | |
| SCHEMBL16371052 | 0.81 | PLG (0.46) | PLGPLAUHTR7CYP19A1KMT2A | |
| SCHEMBL30672928 | 0.81 | PLG (0.46) | PLGPLAUHTR7CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-112592334-A | Pyrimidine derivatives as kinase inhibitors | 艾森生物科学公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-25 | — | — | US | disclosed |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2018-09-06 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-8399477-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESO A.C.R.A.F. S.P.A. (IT) | 2013-03-19 | — | — | US | disclosed |
| CN-101910127-B | (AZA) INDOLE DERIVATIVE SUBSTITUTED IN THE 5 POSITION, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, INTERMEDIATE COMPOUND AND PROCESS FOR PREPARING THE SAME | ACRAF | 2013-01-23 | — | — | CN | disclosed |
| EP-2444392-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2012-04-25 | — | — | EP | disclosed |
| CN-101910127-A | (AZA) INDOLE DERIVATIVE SUBSTITUTED IN THE 5 POSITION, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, INTERMEDIATE COMPOUND AND PROCESS FOR PREPARING THE SAME | ACRAF | 2010-12-08 | — | — | CN | disclosed |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chim. Riun.Ang.Franc. A.C.R.A.F.S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
| EP-2078711-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090076275-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076275-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | PLG 4343/4885PLAU 4552/4885HTR7 87/4885 |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | PTGES, PTGS1, PTGIS | PLG 308/4885PLAU 2315/4885HTR7 3072/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | PLG 1526/4885PLAU 2921/4885HTR7 1409/4885 |
| US-20090076275-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | PLG 1840/4885PLAU 1522/4885HTR7 2601/4885 |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | PLG 1526/4885PLAU 2921/4885HTR7 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.